Assessing Pharmacokinetics and Safety of Therapeutic Alpha-1-Microglobulin in First-in-Human Kidney Transplantation: A Noncomparative Open-Label Multiple-Dose Phase 1b Study
Based on the safety data obtained from 8 subjects in the 2 dose cohorts treated with RMC-035, the drug was considered safe. Safety and AE profiles were in line with expectations of the target population, and infusion-related reactions were short-lived and manageable. Dose-limiting toxicity signals were not observed.
Authors
- Greg Nowak (ORCID: https://orcid.org/0000-0001-8766-8860)
- Lars Wennberg (ORCID: https://orcid.org/0000-0002-3313-3374)
- Sara Thuresson (ORCID: https://orcid.org/0000-0001-8243-3632)
- Johan Nordström (ORCID: https://orcid.org/0000-0002-7443-9521)
- Michael Reusch
- Tobias E. Larsson
Institutions
- Karolinska University Hospital (SE)
- Columbia University Irving Medical Center (US)
- Karolinska Institutet (SE)
- Columbia University (US)
Publication Details
- Journal
- Transplantation Direct
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1097/txd.0000000000001727
- Citations
- 1
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.51